Abstract

NOABSTRACT

Graves' disease (GD) is an autoimmune disease that affects the thyroid and the eyes. Graves' ophthalmopathy (GO), an autoimmune disease, usually appears 18 months after GD diagnosis. Clinical activity and disease severity determine the strategy, with steroid treatment recommended during active disease progression.

This review aims to provide an overview of steroid therapy in the treatment of Graves' ophthalmopathy, discussing its efficacy, protocols, and considerations.

We reviewed the papers focusing on management recommendations and assessed peer-reviewed publications using the following keywords: "Graves' disease", "Graves' ophthalmopathy", "Graves' orbitopathy", "glucocorticoids".

Steroid therapy, especially glucocorticoids, is a primary pharmacologic intervention for clinically active GO. Intravenous administration has shown superior outcomes compared to oral administration, with a recommended protocol that uses a cumulative dose of 4.5 grams methylprednisolone. High-dose systemic glucocorticoids possess anti-inflammatory and immunosuppressive characteristics and are efficacious in managing moderate to severe active GO. Second-line therapies, such as methylprednisolone monotherapy or in com-bination with cyclosporine, may be considered.

Graves' ophthalmopathy re-quires intravenous glucocorticoids during the active phase. Intravenous glucocorticoids are more effective and better tolerated than oral glucocorticoids. Patients with Graves' ophthalmopathy require individualized treatment plans that address contraindications and side effects to improve outcomes and quality of life.

Details

Title
Steroid Treatment Focused Management of Graves’ Ophthalmopathy
Author
Condeng, Y H 1   VIAFID ORCID Logo  ; Umar, H 2   VIAFID ORCID Logo  ; Aman, A M 2   VIAFID ORCID Logo  ; Rasyid, H 3   VIAFID ORCID Logo  ; Bakri, S 3   VIAFID ORCID Logo  ; Iskandar, H 4   VIAFID ORCID Logo 

 Department of Internal Medicine, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia 
 Endocrinology, Metabolism and Diabetes Division, Department of Internal Medicine, Faculty of Medicine, Hasanuddin University – Makassar, Indonesia 
 Nephrology and Hypertension Division, Department of Internal Medicine, Faculty of Medicine, Hasanuddin University – Makassar, Indonesia 
 Pulmonary Disease and Critical Care Medicine Division, Department of Internal Medicine, Faculty of Medicine, Hasanuddin University – Makassar, Indonesia 
Pages
165-170
Publication year
2024
Publication date
2024
Publisher
De Gruyter Poland
ISSN
27195384
e-ISSN
03241750
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
3159554084
Copyright
© 2024. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0 (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.